Table 4.
Canonical pathways enriched using 1956 genes from discovery set with adjusted p-value <0.05
| Ingenuity canonical pathways | -log(p) | P (adj) | Molecules |
|---|---|---|---|
| Molecular Mechanisms of Cancer |
4.54 |
0.003 |
RAP2B,PLCB2,JAK1,DIRAS3,PIK3R1,SMAD3,TAB2,CCND1,MYC,PTK2, CTNNA2,CAMK2D,RHOG,RHOB…. |
| Neuropathic Pain Signaling In Dorsal Horn Neurons |
4.42 |
0.003 |
PLCB2,CAMK4,GRIA1,PIK3R1,GNA11,TAC1,GNA14,GRIA4,TACR1,CAMK2D,PIK3C3,CREB1,CAMK1G … |
| Calcium Signaling |
4.24 |
0.003 |
RAP2B,CAMK4,CALM,GRIA1,TNNT2,HDAC9,CREB5,GRIA4,CABIN1,NFAT5,CAMK2D…. |
| Cellular Effects of Sildenafil (Viagra) |
4.2 |
0.003 |
PLCB2,CAMK4,CALM1,CACNA1S,PDE3A,GNA11,GNA14,PDE4D…. |
| Glutamate Receptor Signaling |
4.15 |
0.003 |
GRIN2B,CALML5,CAMK4,CALM1,SLC17A6,GRID2,GRIA1,GRIK3,SLC1A3,GRIA4,GNG7,…. |
| Axonal Guidance Signaling |
4.11 |
0.003 |
PLCB2,PIK3R1,NTN1,PTK2,NCK2,EPHB1,SEMA3D,UNC5D…. |
| ILK Signaling |
3.99 |
0.004 |
MAP2K6,TMSL3,PPP2R2A,PIK3R1,DIRAS3,BMP2,HIF1A,CREB5,CCND1,PGF,PTK2,NCK2,MYC…. |
| Nitric Oxide Signaling in the Cardiovascular System |
3.49 |
0.0108 |
PDE2A,CALML5,GUCY1B2,CACNA1D,CAMK4,CALM1,GUCY1A3,CACNA1S,PIK3R1…. |
| Gap Junction Signaling |
3.27 |
0.0150 |
PLCB2,PIK3R1,GNA11,GNA14,TUBB2B,SP3,ADCY5,PIK3C3,PRKAR1B,CAV1,PRKCE,CTNNB1,ACTC1…. |
| Role of NFAT in Cardiac Hypertrophy |
3.23 |
0.0150 |
MAP2K6,PLCB2,CAMK4,CALM1,PIK3R1,GNA11,HDAC9,GNA14…. |
| BMP signaling pathway |
3.19 |
0.0150 |
CAMK4,GRB2,RRAS,BMP2,SMAD6,SMAD7,ZNF423,BMPR1B,JUN,PRKAR2B,MAP3K7,CREB1,PRKAR1B…. |
| Dopamine-DARPP32 Feedback in cAMP Signaling |
3.17 |
0.0150 |
PLCB2,CAMK4,CALM1,PPP2R2A,CACNA1S,GNA11,GNA14,CREB5,KCNJ4,ADCY5,CREB1,PRKAR1B… |
| CREB Signaling in Neurons |
3.07 |
0.0161 |
PLCB2,CAMK4,CALM1,PIK3R1,GRIA1,GRID2,GNA11,GNA14,CREB5,GRIA4,GNG7,GRIK5,CAMK2D,GRID1…. |
| N-Glycan Biosynthesis |
3.04 |
0.0161 |
B4GALT4,ALG2,MGAT4A,MAN1C1,B4GALT1,ST6GAL2,MAN1A1,MGAT5,MAN1A2,MAN2A1,B4GALT5,FUT4 |
| cAMP-mediated signaling |
3.04 |
0.0161 |
AKAP12,CAMK4,CALM1,PTGER3,PDE3A,TAAR1,CREB5,CHRM3,CHRM1,PDE4D,HTR1B,CAMK2D,ADCY5…. |
| Factors Promoting Cardiogenesis in Vertebrates |
2.98 |
0.0174 |
SMAD2,FZD10,NOX4,TCF4,BMP2,FZD1,TCF3,FZD8,BMPR1B,MAP3K7 (includes EG:172842),PRKCE…. |
| Melatonin Signaling |
2.89 |
0.0201 |
MAP2K6,CALML5,PLCB2,CAMK4,MTNR1A,CALM1,GNA11,PLCL2,GNA14,CAMK2D,PRKAR2B,RORA…. |
| Synaptic Long Term Potentiation |
2.77 |
0.0235 |
GRIN2B,CALML5,PLCB2,CAMK4,CALM1,RRAS,GRIA1,GNA11,ITPR1,CREB5,GRIA4,GRIN3A,GRM7…. |
| Amyotrophic Lateral Sclerosis Signaling |
2.75 |
0.0235 |
GRIN2B,CACNA1D,GDNF,CAPN11,GRID2,CACNA1S,GRIA1,PIK3R1,GRIK3,GRIA4,GRIN3A,PGF,GRIK5…. |
| Phospholipase C Signaling |
2.73 |
0.0235 |
PLCB2,CAMK4,CALM1,DIRAS3,HDAC9,PLA2G2A,CREB5,GNG7,PLA2G4E,RHOG,NFAT5,RHOB,ADCY5…. |
| PI3K Signaling in B Lymphocytes |
2.73 |
0.0235 |
PLCB2,CAMK4,CALM1,PIK3R1,GNA11,GNA14,PTPRC,NFAT5,JUN,CAMK2D,CREB1,IRS2,PPP3CA…. |
| Synaptic Long Term Depression |
2.7 |
0.0241 |
PLCB2,PPP2R2A,GRID2,GRIA1,GNA11,PLA2G2A,GNA14,GRIA4,PLA2G4E,GRID1…. |
| PPARα/RXRα Activation |
2.6 |
0.0290 |
MAP2K6,PLCB2,NCOA6,SMAD3,GNA11,GNA14,IL6,CHD5,JUN,MAP3K7,ADCY5,PRKAR1B,PRKAA1…. |
| TGF-β Signaling |
2.44 |
0.0386 |
MAP2K6,SMAD2,INHA,GRB2,RRAS,BMP2,SMAD3,SMAD6,SMAD7,ZNF423,GSC,BMPR1B,PIAS4…. |
| Protein Kinase A Signaling |
2.44 |
0.0386 |
PLCB2,PDE3A,SMAD3,CREB5,PDE4D,NTN1,PTK2,CAMK2D,ADCY5,RYR3,PDE2A,YWHAE,PTCH1…. |
| N-Glycan Degradation |
2.38 |
0.0426 |
MANEA,GBA3,MAN1C1,SI,MAN1A1,HEXB,MAN1A2,MAN2A1 |
| Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes |
2.36 |
0.0430 |
VAV2,SMAD2,CALML5,CAMK4,CALM1,GRB2,RRAS,SMAD3,MALT1,NFAT5,JUN,VAV3,ZAP70,MAPK10…. |
| Wnt/β-catenin Signaling |
2.32 |
0.0454 |
FZD10,TCF4,PPP2R2A,TLE1,FZD1,SOX13,CCND1,SOX2,MYC,SOX9,JUN,NLK,MAP3K7…. |
| Agrin Interactions at Neuromuscular Junction |
2.26 |
0.0498 |
RRAS,ITGA6,ITGA3,LAMC1,PTK2,JUN,NRG3,ERBB4,MUSK,LAMB1,MAPK10…. |
| Colorectal Cancer Metastasis Signaling | 2.25 | 0.0498 | FZD10,TCF4,JAK1,PTGER3,PIK3R1,DIRAS3,MMP16,SMAD3,FZD1,IL6,CCND1,GNG7,BIRC5,PGF…. |
Ingenuity Pathway Analysis of the 1956 genes identified 30 significantly enriched pathways.